Status:
UNKNOWN
A-EYE: A Mixed Quantitative and Qualitative Study to Develop and Evaluate the Application of Artificial Intelligence (AI) Methods Using Retinal Imaging for the Identification of Adverse Retinal Changes Associated With Cancer Therapies.
Lead Sponsor:
University of Manchester
Collaborating Sponsors:
Institute of Cancer Research, United Kingdom
Conditions:
All Comers
Eligibility:
All Genders
18+ years
Brief Summary
This is a data collection study involving the gathering of clinical data and OCT (optical coherence tomography) scans from 350 patients. The purpose of this study is to gather data to help develop an...
Detailed Description
Many cancer patients will access new treatments through clinical trials. These treatments have often never been tested in humans and therefore, are likely to have unknown side effects. Some of these s...
Eligibility Criteria
Inclusion
- Patients are eligible for the study if all inclusion criteria are met:
- Voluntary informed consent.
- Aged at least 18 years.
- Fully registered patient attending the Manchester Royal Eye Hospital
- Patients are having an optical diagnostic imaging as part of their standard of care.
Exclusion
- Patients are excluded from the study if any of the following criteria apply:
- 1\. Patient who are deemed clinically unable to be scanned by healthcare professional.
Key Trial Info
Start Date :
June 18 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT04901468
Start Date
June 18 2021
End Date
December 31 2022
Last Update
November 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Manchester Royal Eye Hospital
Manchester, United Kingdom